[PS2] Presidential Session 2
【E】

[PS2-3] Neoadjuvant Pembrolizumab/Placebo + Chemo, Followed by Adjuvant Pembrolizumab/Placebo in Early TNBC: Asian Subgroup

^○高橋 將人¹, Cortés Javier², Dent Rebecca³, Pusztai Lajos⁴, McArthur Heather⁵, Kümmel Sherko⁶, Denkert Carsten⁷, Park Yeon Hee⁸, Im Seock-Ah⁹, Ahn Jin-Hee¹⁰, 向井 博文¹¹, Huang Chiun-Sheng¹², Chen Shin-Cheh¹³, Kim Min Hwan¹⁴, Jia Liyi¹⁵, Li Xin Tong¹⁵, Tryfonidis Konstantinos¹⁵, Karantza Vassiliki¹⁵, 岩田 広治¹⁶, Schmid Peter¹⁷ (1.国立病院機構北海道がんセンター 乳腺外科, 2.Oncology Department, IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, 3.National Cancer Center Singapore, Duke-NUS Medical School, Singapore, 4.Yale Cancer Center, Yale University School of Medicine, New Haven, CT, USA, 5.UT Southwestern Medical Center, Dallas, TX, USA, 6.Breast Unit, Kliniken Essen-Mitte Evang, Huyssens-Stiftung, Essen, Germany, 7.Institute of Pathology, Philipps University Marburg, Marburg, Germany, 8.Hematology-Oncology, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 9.Seoul National University Hospital, Cancer Research Institute, Seoul National University, Seoul, Republic of Korea, 10.Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, 11.国立がん研究センター東病院 腫瘍内科, 12.National Taiwan University Hospital, Taipei, Taiwan, 13.Chang Gung University Medical College, Taipei, Taiwan, 14.Yonsei University College of Medicine, Seoul, South Korea, 15.Merck & Co., Inc., Kenilworth, NJ, USA, 16.愛知県がんセンター病院 乳腺科部, 17.Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK)